GB0900555D0 - New methods - Google Patents

New methods

Info

Publication number
GB0900555D0
GB0900555D0 GBGB0900555.4A GB0900555A GB0900555D0 GB 0900555 D0 GB0900555 D0 GB 0900555D0 GB 0900555 A GB0900555 A GB 0900555A GB 0900555 D0 GB0900555 D0 GB 0900555D0
Authority
GB
United Kingdom
Prior art keywords
new methods
new
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0900555.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onxeo DK
Original Assignee
Topotarget AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget AS filed Critical Topotarget AS
Priority to GBGB0900555.4A priority Critical patent/GB0900555D0/en
Publication of GB0900555D0 publication Critical patent/GB0900555D0/en
Priority to MX2011007373A priority patent/MX2011007373A/en
Priority to JP2011544847A priority patent/JP2012515143A/en
Priority to PCT/EP2010/000077 priority patent/WO2010081662A2/en
Priority to EP10701451A priority patent/EP2387397A2/en
Priority to CA2749051A priority patent/CA2749051A1/en
Priority to US12/657,160 priority patent/US20100190694A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0900555.4A 2009-01-14 2009-01-14 New methods Ceased GB0900555D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0900555.4A GB0900555D0 (en) 2009-01-14 2009-01-14 New methods
MX2011007373A MX2011007373A (en) 2009-01-14 2010-01-11 Methods for identifying patients who will respond well to cancer treatment.
JP2011544847A JP2012515143A (en) 2009-01-14 2010-01-11 Methods for identifying patients who respond well to cancer therapy
PCT/EP2010/000077 WO2010081662A2 (en) 2009-01-14 2010-01-11 Methods for identifying patients who will respond well to cancer treatment
EP10701451A EP2387397A2 (en) 2009-01-14 2010-01-11 Methods for identifying patients who will respond well to cancer treatment
CA2749051A CA2749051A1 (en) 2009-01-14 2010-01-11 Methods for identifying patients who will respond well to cancer treatment
US12/657,160 US20100190694A1 (en) 2009-01-14 2010-01-14 Methods for identifying patients who will respond well to cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0900555.4A GB0900555D0 (en) 2009-01-14 2009-01-14 New methods

Publications (1)

Publication Number Publication Date
GB0900555D0 true GB0900555D0 (en) 2009-02-11

Family

ID=40379541

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0900555.4A Ceased GB0900555D0 (en) 2009-01-14 2009-01-14 New methods

Country Status (7)

Country Link
US (1) US20100190694A1 (en)
EP (1) EP2387397A2 (en)
JP (1) JP2012515143A (en)
CA (1) CA2749051A1 (en)
GB (1) GB0900555D0 (en)
MX (1) MX2011007373A (en)
WO (1) WO2010081662A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012236142A1 (en) * 2011-04-01 2013-10-17 Threshold Pharmaceuticals, Inc. Methods for treating cancer
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
WO2017070441A1 (en) * 2015-10-23 2017-04-27 Icahn School Of Medicine At Mount Sinai Identifying and treating cancer patients who are suitable for a targeted therapy using an hdac6 inhibitor
CN108685947A (en) * 2017-04-11 2018-10-23 上海尚泰生物技术有限公司 Colorectal cancer hepatic metastases primary tumor and transfer stove match model

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
CZ20011342A3 (en) * 1998-10-13 2001-09-12 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptides
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
ES2223705T3 (en) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER THROUGH INHIBITION SELECTIVE OF VEGF.
EP1233958B1 (en) * 1999-11-23 2011-06-29 MethylGene Inc. Inhibitors of histone deacetylase
US6888027B2 (en) * 2000-09-29 2005-05-03 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
ATE310719T1 (en) * 2000-09-29 2005-12-15 Topotarget Uk Ltd CARBAMINIC ACID DERIVATIVES CONTAINING AN AMIDE GROUP AS HDAC INHIBITORS
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
AU2002237261A1 (en) * 2001-01-09 2002-07-24 Novartis Pharma Gmbh Rapid method for screening compounds for in vivo activity
JPWO2002074298A1 (en) * 2001-03-21 2004-07-08 小野薬品工業株式会社 IL-6 production inhibitor
BR0211810A (en) * 2001-08-09 2004-08-24 Ono Pharmaceutical Co Carboxylic acid derivatives and pharmaceutical agent comprising them as active ingredient
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
CA2467629A1 (en) * 2001-11-20 2003-05-30 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
US7041699B2 (en) * 2002-01-11 2006-05-09 Matthias Rath Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
JP2005525345A (en) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Methods for treating TRX-mediated diseases
US20050288227A1 (en) * 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
AU2003213684C1 (en) * 2002-03-04 2008-10-23 Merck Hdac Research, Llc Methods of inducing terminal differentiation
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7495022B2 (en) * 2002-04-11 2009-02-24 Sk Chemicals Co., Ltd. α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
CN100566711C (en) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 Compounds for treating cancer and uses thereof
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US20060089322A1 (en) * 2002-05-01 2006-04-27 Mark Vincent Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
WO2004064727A2 (en) * 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
JP2006520796A (en) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
US7606215B2 (en) * 2003-04-07 2009-10-20 Paul Poniatowski Audio/visual information dissemination system
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
PL379887A1 (en) * 2003-08-26 2006-11-27 Merck Hdac Research, Llc Method of treating cancer with hdac inhibitors
ATE353107T1 (en) * 2003-08-28 2007-02-15 Hoffmann La Roche DEPENDENCE OF SYMPTOM-FREE SURVIVAL OF 5-FU TREATED COLON CANCER PATIENTS ON THE RATIO OF THE MRNA EXPRESSION LEVEL OF THYMIDINE PHOSPHORYLASE AND DIHYDROPYRIMIDINE DEHYDROGENASE
CA2590257A1 (en) * 2003-11-14 2005-06-09 Per Sonne Holm Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
JP2007511211A (en) * 2003-11-14 2007-05-10 ホルム，ペル・ゾンネ New use of adenovirus and nucleic acid encoding it
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
WO2005085864A1 (en) * 2004-02-27 2005-09-15 The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services Pharmacodynamic assays using flow cytometry
SI1591109T1 (en) * 2004-04-30 2008-10-31 Topotarget Germany Ag Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
EP1787657A1 (en) * 2004-08-06 2007-05-23 Ono Pharmaceutical Co., Ltd. Therapeutic agent for psychoneurotic disease
CN101001851B (en) * 2004-08-09 2011-04-20 安斯泰来制药有限公司 Hydroxyamide compounds having activity as inhibitors of histone deacetylase (HDAC)
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
US20090232800A1 (en) * 2004-12-31 2009-09-17 Per Sonne Holm E1-minus adenoviruses and use thereof
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
EP2502649A1 (en) 2005-02-03 2012-09-26 TopoTarget UK Limited Combination therapy using HDAC inhibitors and erlotinib for treating cancer
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
ATE542527T1 (en) * 2005-05-13 2012-02-15 Topotarget Uk Ltd PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
US20080292616A1 (en) * 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
KR20080042170A (en) * 2005-09-07 2008-05-14 플렉시콘, 인코퍼레이티드 PPC active compound
WO2007031091A2 (en) * 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
CA2627923C (en) 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EA015151B1 (en) * 2006-02-22 2011-06-30 4ЭсЦэ АГ Indolopyridines as eg5 kinesin modulators
JP5349056B2 (en) * 2006-02-22 2013-11-20 ４エスツェー アクチェンゲゼルシャフト Indropyridines as Eg5 kinesin modulators
WO2007109178A2 (en) * 2006-03-16 2007-09-27 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2008011603A2 (en) * 2006-07-20 2008-01-24 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US7915245B2 (en) * 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
US8012695B2 (en) * 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
WO2008116163A1 (en) * 2007-03-22 2008-09-25 Oregon Health & Science University Therapeutic drug combinations for treatment of b-cell malignancies
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
WO2008154402A2 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
WO2009137649A2 (en) * 2008-05-07 2009-11-12 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Also Published As

Publication number Publication date
WO2010081662A2 (en) 2010-07-22
WO2010081662A3 (en) 2010-09-23
US20100190694A1 (en) 2010-07-29
EP2387397A2 (en) 2011-11-23
JP2012515143A (en) 2012-07-05
MX2011007373A (en) 2011-08-08
CA2749051A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
DK3023438T3 (en) Anti-gitr-antistoffer
DK2457337T3 (en) Specialtilpasset impuls-burst
DK2442650T4 (en) Sublingualt apomorfin
GB0907413D0 (en) Novel methods
GB0909645D0 (en) Methods
GB0907350D0 (en) Methods
EP2519921A4 (en) Call-tracking
GB0901001D0 (en) Methods
DK2464943T3 (en) Systemintegration
GB0912685D0 (en) Methods
GB0900555D0 (en) New methods
GB0912159D0 (en) Methods
GB0907601D0 (en) Novel methods
GB0900319D0 (en) Hydrocharger
EP2510125A4 (en) Hyperprimers
GB0900280D0 (en) Methods
GB0901232D0 (en) Methods
GB0904209D0 (en) Methods
GB0912624D0 (en) Methods
AU4924P (en) Bonscablue Scaevola aemula
AU4925P (en) Bonscawi Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
GB0901387D0 (en) VisiClip
GB0900953D0 (en) Leggettes
GB0900212D0 (en) Shelta

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)